Complications and treatment patterns in patients with non-transfusion-dependent α- and β-thalassemia compared with matched controls: a retrospective observational study using administrative claims data in the United States
Frontiers in Hematology · 30.03.2026 · 5
DOI: 10.3389/frhem.2026.1770034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Hematology, online erschienen am 30.03.2026. Verfasst von Arielle L. Langer und 6 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agios Pharmaceuticals.
Abstract (Originalsprache)
Background
Non-transfusion-dependent thalassemia (NTDT) can result in a range of clinical complications that can substantially reduce patient quality of life. To date, real-world studies on the clinical burden of the disease have focused on Europe and Asia and have been limited to β-NTDT.
Aim
To assess the complications and treatment patterns in patients with α- or β-NTDT vs. matched controls in the United States (US).
Methods
This retrospective observational study used data from US claims databases (January 1, 2013–June 30, 2021). Adult patients (≥18 years) with ≥1 inpatient or ≥2 outpatient claims for α- or β-thalassemia were included from Merative ™ MarketScan ® Commercial/Medicare and Multi-State Medicaid databases. Patients were classified as NTDT if they had <8 blood transfusions or ≥6 weeks between any two adjacent transfusions during the 12 months post-index date (date of first observed α- or β-thalassemia diagnosis code). Patients were matched with controls (1:5 ratio). Primary analysis focused on patients from the Commercial/Medicare database with mean hemoglobin <10 g/dL during follow-up, to minimize inclusion of patients with thalassemia trait. Complications and treatment patterns were assessed during ≥12 months post-index. Comparisons between patients with NTDT vs. controls were performed using Chi-square tests (categorical variables) and t-tests (continuous variables) (two-sided significance level of 0.05). Analyses for the α- and β-NTDT subgroups were also performed.
Results
In the Commercial/Medicare database, 149 patients with NTDT and hemoglobin <10 g/dL were matched with 745 controls (mean follow-up approximately 3 years). A significantly higher percentage of patients with NTDT had complications vs. controls, including malignancy (17.4% vs. 7.1%; p < 0.001), cardiovascular disease (15.4% vs. 7.8%; p = 0.003), liver disease (6.7% vs. 0.5%; p < 0.001), and gallstones (6.7% vs. 2.1%; p = 0.002). Overall, 18.8% of patients with NTDT had ≥1 transfusion; 4.0% received oral chelators. Similar trends across outcomes were observed for NTD α- and β-thalassemia subgroups vs. controls.
Conclusions
Patients with NTDT had a high disease burden and experienced a range of serious complications, with significantly higher rates compared with controls. Additional effective and well-tolerated treatments are needed to address the underlying causes of NTDT and prevent complications.
Förderung
- Agios Pharmaceuticals
Zitieren
APA
Langer, A. L., Rane, A., Gilroy, K. S., Zhao, J., Lombard, L., Lew, C. R., & Sheth, S. (2026). Complications and treatment patterns in patients with non-transfusion-dependent α- and β-thalassemia compared with matched controls: a retrospective observational study using administrative claims data in the United States. Frontiers in Hematology, 5. https://doi.org/10.3389/frhem.2026.1770034
Vancouver
Langer AL, Rane A, Gilroy KS, Zhao J, Lombard L, Lew CR, et al. Complications and treatment patterns in patients with non-transfusion-dependent α- and β-thalassemia compared with matched controls: a retrospective observational study using administrative claims data in the United States. Frontiers in Hematology. 2026;5. doi:10.3389/frhem.2026.1770034
BibTeX
@article{Langer2026,
author = {Langer, Arielle L. and Rane, Amey and Gilroy, Keely S. and Zhao, Jing and Lombard, Louise and Lew, Carolyn R. and Sheth, Sujit},
title = {Complications and treatment patterns in patients with non-transfusion-dependent α- and β-thalassemia compared with matched controls: a retrospective observational study using administrative claims data in the United States},
journal = {Frontiers in Hematology},
year = {2026},
volume = {5},
doi = {10.3389/frhem.2026.1770034}
}
EUVIMED